title: Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.
abstract: OBJECTIVE
  The aim of this systematic review was to examine and compare differences in the way medication exposures are classified in studies using linked administrative data to investigate outcomes following medication use during pregnancy. This was undertaken with a focus on studies investigating specific neonatal outcomes following prenatal exposure to selective serotonin reuptake inhibitors (SSRIs).
  
  
  METHODS
  We searched Medline and Embase to identify studies that used linked administrative data to investigate specific neonatal outcomes (congenital malformations, birth weight, gestational age) following prenatal exposure to SSRIs.
  
  
  RESULTS
  Key factors such as dose, duration and timing of exposure were inconsistently addressed in the studies identified. In addition, there was a great deal of variability in the way medication exposures were classified and how women who stop taking their medication before or during early pregnancy are handled in analyses. Furthermore, there are issues in assuming how and when women who receive a dispensing for a medication actually take it during pregnancy. This creates a great deal of uncertainty around medication exposure during pregnancy in studies using linked administrative data, potentially resulting in biased risk estimates.
  
  
  CONCLUSIONS
  There is a need for greater focus on determining the most effective and accurate way of using linked administrative data to investigate outcomes following medication use during pregnancy in an effort to minimise potential biases.
authors.affiliation: Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia. grzly001@mymail.unisa.edu.au
authors.forename: Luke E
authors.initials: LE
authors.lastname: Grzeskowiak
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Gilbert
authors.forename: Janna L
authors.initials: JL
authors.lastname: Morrison
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000175:diagnosis; D001724:Birth Weight / Q000187:drug effects; D011307:Drug Prescriptions; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D008498:Medical Record Linkage; D055118:Medication Adherence; D017891:Pharmacoepidemiology / Q000379:methods*; D011247:Pregnancy; D047928:Premature Birth / Q000139:chemically induced; D055553:Prescription Drugs / Q000008:administration & dosage / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D055553:Prescription Drugs; D017367:Selective Serotonin Reuptake Inhibitors
references.citation: Am J Psychiatry. 2002 Dec;159(12):2055-61
references.pmid: 12450956
references.citation: Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):243-8
references.pmid: 21351305
references.citation: Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1086-94
references.pmid: 17729378
references.citation: Clin Epidemiol. 2010 Aug 09;2:29-36
references.pmid: 20865100
references.citation: N Engl J Med. 2003 Dec 25;349(26):2556-9
references.pmid: 14695418
references.citation: Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1181-3
references.pmid: 17966108
references.citation: Br J Psychiatry. 2008 May;192(5):338-43
references.pmid: 18450656
references.citation: J Clin Pharmacol. 2011 Feb;51(2):264-70
references.pmid: 20663997
references.citation: Obstet Gynecol. 2005 Dec;106(6):1289-96
references.pmid: 16319254
references.citation: Congenit Anom (Kyoto). 2005 Jun;45(2):44-51
references.pmid: 15904431
references.citation: Am J Obstet Gynecol. 2006 Apr;194(4):961-6
references.pmid: 16580283
references.citation: Arch Gen Psychiatry. 2006 Aug;63(8):898-906
references.pmid: 16894066
references.citation: Drug Saf. 2011 Nov 1;34(11):1027-48
references.pmid: 21981432
references.citation: Pharmacoepidemiol Drug Saf. 2007 May;16(5):474-84
references.pmid: 16897811
references.citation: Aust N Z J Public Health. 1999 Oct;23(5):453-9
references.pmid: 10575763
references.citation: Epidemiology. 2006 Nov;17(6):701-4
references.pmid: 17028507
references.citation: Pediatr Rev. 2001 May;22(5):153-65
references.pmid: 11331737
references.citation: BMJ. 2009 Sep 23;339:b3569
references.pmid: 19776103
references.citation: Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1075-85
references.pmid: 17729379
references.citation: Clin Epidemiol. 2011 Feb 01;3:43-50
references.pmid: 21386973
references.citation: Am J Epidemiol. 2008 Mar 15;167(6):633-40
references.pmid: 18194999
references.citation: Br J Clin Pharmacol. 2008 Apr;65(4):600-6
references.pmid: 17953715
references.citation: Drug Saf. 2000 Mar;22(3):169-77
references.pmid: 10738841
references.citation: Pediatrics. 2005 Dec;116(6):e833-8
references.pmid: 16322141
references.citation: Reprod Toxicol. 2008 Sep;26(1):36-41
references.pmid: 18588969
references.citation: Birth Defects Res A Clin Mol Teratol. 2011 Mar;91(3):142-52
references.pmid: 21381184
references.citation: Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):18-27
references.pmid: 17187388
references.citation: Epidemiology. 2001 Sep;12(5):497-501
references.pmid: 11505166
references.citation: Eur J Clin Pharmacol. 2011 Aug;67(8):839-45
references.pmid: 21387167
references.citation: Birth Defects Res B Dev Reprod Toxicol. 2008 Feb;83(1):68-76
references.pmid: 18293409